RT Journal Article
SR Electronic
T1 Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.18.20105650
DO 10.1101/2020.05.18.20105650
A1 Laurent Chouchana
A1 Sana Boujaafar
A1 Ines Gana
A1 Laure-Hélène Preta
A1 Lucile Regard
A1 Paul Legendre
A1 Celia Azoulay
A1 Etienne Canouï
A1 Jeremie Zerbit
A1 Nicolas Carlier
A1 Benjamin Terrier
A1 Solen Kerneis
A1 Rui Batista
A1 Jean-Marc Treluyer
A1 Yi Zheng
A1 Sihem Benaboud
YR 2020
UL http://medrxiv.org/content/early/2020/05/22/2020.05.18.20105650.abstract
AB Background There is an urgent need of active treatment for coronavirus disease 2019 (Covid-19). Although efficacy have not been proven, lopinavir/ritonavir 400 mg/100 mg twice daily has been proposed as a treatment of moderate to severe Covid-19. Previously published cohorts showed Covid-19 is associated with major inflammation. To date, no data are available regarding lopinavir/ritonavir plasma concentration and its safety in Covid-19 patients.Methods Real-world Covid-19 experience based on a retrospective cohort study.Results On the cohort of 31 patients treated by lopinavir/ritonavir for Covid-19, we observed very high lopinavir plasma concentrations, increased of 4.6-fold (IQR 2.9-6.4), with regards to average plasma concentrations in HIV treatment. All except two patients were above the upper limit of the concentration ranges of HIV treatment. In this cohort, about one over four to five patients prematurely stopped lopinavir/ritonavir therapy due to a moderate adverse drug reaction, mainly hepatic and gastrointestinal disorders.Conclusion Patients with Covid-19 pneumonitis treated with lopinavir/ritonavir have plasma concentrations dramatically higher than expected. Owing to that high plasma concentration may be required for antiviral activity against SARS-CoV-2, it appears that lopinavir dosage should not be reduced in the absence of adverse effect. About 80% of the patients well tolerated lopinavir/ritonavir therapy under these plasma concentrations. However, cautious is necessary as drug repurposing can be associated with a new drug safety profile.Funding NoneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request